Co-Founder, President & Chief Executive Officer
Niven R. Narain is Co-Founder, President, & CEO of BERG. His foremost passion is to improve healthcare systems and patient care through the fusion of AI and patient biology to develop the next generation of therapeutics. As CEO, Niven drives the vision of BERG's translational engine from discovery to clinical development and ensures that BERG is collaborating with like-minded institutions to advance product development. He discovered Interrogative Biology®, BERG’s flagship platform that has created a robust pipeline of products in cancer, diabetes, and CNS diseases. BPM 31510 is BERG’s lead asset in solid tumors which is currently in Phase II trials. He is inventor on over 600 issued and pending patents over a diverse range of assets in drugs and diagnostics.
Senior Vice President & Chief Operating Officer
Titus Plattel is the Chief Operating Officer for BERG. His experience spans over 25 years in global biotech companies which gave Titus a broad experience in all facets of product development and commercialization of innovative therapies across different therapeutic areas. His professional experience spans key functions of product development including program management, portfolio analyses, product marketing and market analysis, pre-launch prep and final product launch by all sales and marketing functions involved.
Senior Vice President & Chief Analytics Officer
Slava Akmaev, Ph.D. is the Senior Vice President and Chief Analytics Officer, leading the Analytics division. Dr. Akmaev is an avid advocate for the application of Artificial Intelligence tools in digital healthcare. He is a frequent speaker at Precision Medicine and Big Data meetings. Prior to his role at BERG Dr. Akmaev was the Scientific Associate Director at Genzyme Genetics where he launched multiple commercial diagnostic products. While at Genzyme R&D he led the development of novel statistical approaches for high-throughput "omics" data and performed analytical work in genomics and genetics. Dr. Akmaev published numerous manuscripts in genomics and was one of the early developers of analytical methodology around high-throughput molecular data. He co-authored the publication of the Long SAGE™ technology, "Using the transcriptome to annotate the genome" in Nature Biotechnology. Dr. Akmaev holds a Ph.D. in Applied Mathematics from the University of Colorado at Boulder. He is a recipient of the prestigious fellowship from The Program in Mathematics and Molecular Biology.
Senior Vice President & Chief Scientific Officer
Dr. Sarangarajan is the Senior Vice President & Chief Scientific Officer at BERG oversees all research & development activities. He is the co-inventor and co-architect of the BERG Interrogative Biology® technology and leads the implementation of scientific strategies and overall operations of the multifunctional integrated scientific program intersecting science and technology. He is responsible for developing strategies for rapid validation of preclinical and translation into clinical development and beyond of drug targets, therapeutics and biomarkers in the areas of cancer, cardiovascular and metabolic diseases, neurological diseases and other area(s) of BERG focus.
Vice President of Finance & Controller
Kevin Coveney is the Vice President of Finance and Controller at BERG. Mr. Coveney drives the company’s financial operations and oversees its corporate Financial, Planning & Analysis and Accounting & Finance departments. Mr. Coveney has more than 25 years of financial management experience including public accounting, SEC reporting experience as well as financial management and reporting in the biotech and technology industries.
Chief Precision Medicine Officer
Michael Kiebish, PhD is the Chief Precision Medicine Officer. Michael joined BERG in 2012 and has overseen numerous technical and translational roles during his tenure. Dr. Kiebish and his team have pioneered novel systems medicine strategies for biomarker, pharmaceutical and theranostic development to ensure target populations’ are stratified based on biological and physiological status. Through the implementation of artificial intelligence platforms, BIG Data integration, population health strategies, and integrative phenomic technologies, the systems medicine division overseen by Dr. Kiebish synergizes BERG’s efforts in improving patient care, stratifying populations, and guiding molecular adaptive clinical trials.
Vice President, Research and Development
Vivek K Vishnudas, Ph. D. is the Vice President of Research & Development and oversees drug/biomarker discovery and development. Dr Vishnudas is a co-inventor of the Interrogative Biology® technology. Dr Vishnudas actively oversees the emerging R&D pipeline for Berg and has been a pioneer in implementing “Big Data” strategies for next generation discovery and development. His breadth of operations covers all aspects pertaining to scientific leadership, translational research and intellectual property strategies.
Ernie Martinez serves as General Counsel in leading corporate strategic and tactical legal initiatives, providing senior management with advice on company strategies and their implementation, managing all aspects of BERG's legal function, and retaining and overseeing the work of outside counsel in specialty areas such as intellectual property, regulatory and litigation. Ernie also works closely with the BERG President and Board of Directors to implement approved policies and initiatives related to pharmaceutical, healthcare, and defense sectors.